Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases

Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases

    - Genzyme to Obtain Significant Global Rights to Alnylam's Pipeline -

 - Alnylam Retains Most Product Rights in North America and Western Europe -

   - Genzyme Becomes Major Alnylam Shareholder through $700 Million Equity
                                 Investment -

PARIS and  CAMBRIDGE, Mass.,  Jan.  14, 2014  (GLOBE NEWSWIRE)  --Genzyme,  a 
Sanofi company (EURONEXT:  SAN and  NYSE: SNY),  and Alnylam  Pharmaceuticals, 
Inc. (NASDAQ:  ALNY) announced  today that  they have  significantly  expanded 
their strategic agreement  to develop  and commercialize  treatments for  rare 
genetic diseases. Genzyme will have significant rights to Alnylam's  portfolio 
of clinical and pre-clinical stage  drug candidates. Alnylam will retain  most 
product  rights  in  North   America  and  Western   Europe,  and  will   have 
significantly  expanded  development  and  commercial  opportunities  for  its 
genetic medicine pipeline through Genzyme's established global  infrastructure 
in rare diseases.

"This collaboration  is  an  important  building  block  for  our  future.  It 
strengthens our pipeline  and provides  us with  the opportunity  to meet  the 
needs  of  patients  with   rare  diseases  around   the  world  through   our 
well-established  global  organization,"  said  David  Meeker,  MD,  Genzyme's 
President and  CEO. "This  transaction  also powerfully  underscores  Sanofi's 
commitment to investing in Genzyme as one of the company's key growth drivers.
Our  partnership  with  Alnylam  has  been  highly  collaborative,  and  their 
world-class RNAi  technology  holds the  promise  to provide  a  platform  for 
sustained drug development for rare genetic diseases for years to come."

"This new relationship with Genzyme is transformational for Alnylam. It is  a 
game changer for both the advancement of  RNAi therapeutics as a new class  of 
genetic medicines to  patients around  the world,  and for  our commitment  to 
build a leading, independent biopharmaceutical company that delivers value  to 
our shareholders," said  John Maraganore,  Ph.D., Chief  Executive Officer  of 
Alnylam. "In this  new alliance, Alnylam  benefits enormously from  Genzyme's 
proven global capabilities, enabling us to accelerate and expand market access
for our 'Alnylam 5x15' products."

In 2012,  Alnylam and  Genzyme formed  an exclusive  alliance to  develop  and 
commercialize  Alnylam's  lead  product,  patisiran,  which  is  in  Phase   3 
development  for  the  treatment   of  transthyretin  (TTR)-familial   amyloid 
polyneuropathy, a  rare  life-threatening  disease that  damages  the  nervous 
system.

The expanded relationship between Genzyme  and Alnylam includes the  following 
components:

First, Genzyme will obtain  expanded rights to  patisiran. Under the  original 
agreement from 2012, Genzyme  had rights to  commercialize patisiran in  Japan 
and the broader  Asia-Pacific region.  This disease  has a  disproportionately 
high prevalence in  these territories. Under  the expanded agreement,  Genzyme 
will now commercialize patisiran in  all territories outside of North  America 
and Western Europe, which are retained by Alnylam for their commercialization.


Second, Genzyme will obtain rights  to commercialize worldwide three  products 
in Alnylam's pipeline. Specifically, (1)  Genzyme and Alnylam will  co-develop 
and co-commercialize ALN-TTRsc, a product currently in Phase 2 development for
the treatment of familial amyloid cardiomyopathy, in North America and Western
Europe, while Genzyme  commercializes the product  in the rest  of world;  (2) 
Genzyme will have the rights to  two additional products after the  completion 
of early clinical trials and will be able to choose between full global rights
or co-commercialization rights, depending on the product.

Third, Genzyme will  have the option  up until 2020,  with the possibility  of 
extension through  the end  of 2021,to  develop and  commercialize outside  of 
North America and Western  Europe all products being  developed to treat  rare 
genetic diseases  from  Alnylam's  pipeline. Alnylam  retains  its  rights  to 
co-develop and co-commercialize its genetic medicine pipeline in North America
and Western Europe. 

Finally, Genzyme  will become  a major  Alnylam shareholder  with a  stake  of 
approximately 12% percent  through a  $700 million  investment at  a price  of 
approximately $80/share, which  represents a  27% premium as  compared to  the 
average share price over the last  30 days. In addition, Alnylam will  receive 
R&D funding,  starting on  January 1,  2015, for  programs where  Genzyme  has 
elected to opt-in for development  and commercialization. Further, Alnylam  is 
eligible to receive milestones and royalties.

This transaction has  been approved by  the boards of  both companies, and  is 
subject to customary  closing conditions and  clearances under the  Hart-Scott 
Rodino Antitrust Improvements Act.

Conference Call Information
Alnylam and Genzyme management will discuss this new alliance in a conference
call on January 13, 2014 at 9:00 am ET (6:00 am PT). A slide presentation
will also be available on the News & Investors page of the company's website,
www.alnylam.com, to accompany the conference call. To access the call, please
dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes
prior to the start time and refer to conference ID 31887205. A replay of the
call will be available beginning at 12:00 pm ET (9:00 am PT) on January 13,
2014. To access the replay, please dial 855-859-2056 (domestic) or
404-537-3406 (international), and refer to conference ID 31887205.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based  on 
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with  a core focus on RNAi therapeutics  for 
the treatment of genetically defined diseases.  As part of its "Alnylam  5x15" 
strategy, as updated in early 2014, the  company expects to have six to  seven 
genetic medicine product  candidates in  clinical development  - including  at 
least two programs in  Phase 3 and  five to six programs  with human proof  of 
concept - by the end of 2015.

About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years.  We 
accomplish our goals through world-class research and with the compassion  and 
commitment of  our employees.  With  a focus  on  rare diseases  and  multiple 
sclerosis, we are dedicated to  making a positive impact  on the lives of  the 
patients and families we  serve. That goal guides  and inspires us every  day. 
Genzyme's  portfolio  of  transformative  therapies,  which  are  marketed  in 
countries around the world, represents groundbreaking and life-saving advances
in medicine.  As  a  Sanofi  company, Genzyme  benefits  from  the  reach  and 
resources of  one of  the  world's largest  pharmaceutical companies,  with  a 
shared  commitment  to  improving  the  lives  of  patients.  Learn  more   at 
www.genzyme.com. Genzyme® is  a registered trademark  of Genzyme  Corporation. 
All rights reserved.

About Sanofi
Sanofi, an  integrated  global  healthcare  leader,  discovers,  develops  and 
distributes therapeutic solutions focused on patients' needs. Sanofi has  core 
strengths in the  field of  healthcare with seven  growth platforms:  diabetes 
solutions, human  vaccines, innovative  drugs, consumer  healthcare,  emerging 
markets, animal  health  and  the  new Genzyme.  Sanofi  is  listed  in  Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward Looking Statements
This press  release  contains forward-looking  statements  as defined  in  the 
Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking 
statements are  statements that  are not  historical facts.  These  statements 
include projections and estimates and their underlying assumptions, statements
regarding plans,  objectives,  intentions  and expectations  with  respect  to 
future financial results,  events, operations,  services, product  development 
and potential, and  statements regarding  future performance.  Forward-looking 
statements are  generally identified  by the  words "expects",  "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions.  Although 
Sanofi's  management  believes  that   the  expectations  reflected  in   such 
forward-looking  statements  are  reasonable,  investors  are  cautioned  that 
forward-looking information and  statements are subject  to various risks  and 
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to  differ 
materially  from  those  expressed  in,  or  implied  or  projected  by,   the 
forward-looking information  and  statements. These  risks  and  uncertainties 
include among  other  things,  the  uncertainties  inherent  in  research  and 
development, future  clinical data  and  analysis, including  post  marketing, 
decisions by regulatory  authorities, such as  the FDA or  the EMA,  regarding 
whether and when to  approve any drug, device  or biological application  that 
may be  filed for  any such  product  candidates as  well as  their  decisions 
regarding labelling and other  matters that could  affect the availability  or 
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and  commercial  success  of therapeutic  alternatives,  the  Group's 
ability to  benefit from  external growth  opportunities, trends  in  exchange 
rates and prevailing interest rates,  the impact of cost containment  policies 
and subsequent changes thereto,  the average number  of shares outstanding  as 
well as those discussed or identified in  the public filings with the SEC  and 
the AMF  made by  Sanofi,  including those  listed  under "Risk  Factors"  and 
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on  Form 20-F  for the  year ended  December 31,  2012. Other  than  as 
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Alnylam Forward-Looking Statements

Various  statements  in  this   press  release  concerning  Alnylam's   future 
expectations, plans  and prospects,  including without  limitation,  Alnylam's 
views with  respect to  the  potential for  RNAi therapeutics,  including  the 
programs in its 5x15 pipeline, Genzyme's participation in the development  and 
commercialization of RNAi therapeutics, its expectations regarding the receipt
of potential R&D payments, development and sales milestones and royalties from
Genzyme, and  its expectations  regarding available  cash for  its  operations 
through multiple product launches,  constitute forward-looking statements  for 
the purposes  of  the safe  harbor  provisions under  The  Private  Securities 
Litigation Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various important
factors, including,  without limitation,  Alnylam's  ability to  discover  and 
develop  novel   drug  candidates   and  delivery   approaches,   successfully 
demonstrate the efficacy and safety  of its drug candidates, the  pre-clinical 
and clinical results for its product candidates, which may not support further
development of product candidates, actions  of regulatory agencies, which  may 
affect the  initiation,  timing and  progress  of clinical  trials,  Genzyme's 
ability to successfully advance patisiran, ALN-TTRsc and other products in the
Genzyme territory,  resulting  in  the potential  payment  of  milestones  and 
royalties  to  Alnylam,  as   well  as  Alnylam's   ability  to  develop   and 
commercialize such products in the rest  of the world, the parties ability  to 
successfully co-develop  and co-promote  ALN-TTRsc  and potentially  a  second 
product in  North  America  and Western  Europe,  obtaining,  maintaining  and 
protecting intellectual  property, Alnylam's  ability to  enforce its  patents 
against infringers and  defend its  patent portfolio  against challenges  from 
third parties, obtaining  regulatory approval for  products, competition  from 
others using technology  similar to Alnylam's  and others developing  products 
for similar uses, Alnylam's  ability to obtain  additional funding to  support 
its  business  activities  and  establish  and  maintain  strategic   business 
alliances and new business initiatives, Alnylam's dependence on third  parties 
for development, manufacture, marketing,  sales and distribution of  products, 
the outcome of litigation, and unexpected expenditures, as well as those risks
more fully discussed in  the "Risk Factors" filed  with Alnylam's most  recent 
Quarterly  Report  on  Form  10-Q  filed  with  the  Securities  and  Exchange 
Commission (SEC) and  in other filings  that Alnylam makes  with the SEC.  In 
addition, any forward-looking statements represent Alnylam's views only as  of 
today and  should not  be relied  upon as  representing its  views as  of  any 
subsequent date. Alnylam  explicitly disclaims any  obligation to update  any 
forward-looking statements.

Contacts:
                                Sanofi Investor Relations
Sanofi Media Relations
                                Sébastien Martel
Jack Cox 
                                Tel: +33 (0) 1 53 77 45 45
Tel: +33 (0) 1 53 77 94 74
                                E-mail: ir@sanofi.com
E-mail: mr@sanofi.com
Genzyme Media Relations
Lori Gorski

Tel: 617-768-9344               Sanofi Investor Relations

E-mail: Lori.gorski@genzyme.com Kristen Galfetti

Alnylam                         Tel: +1 908 981 5560

Cynthia Clayton                 E-mail: ir@sanofi.com

Tel: 617-551-8207

Email: cclayton@alnylam.com

PDF Version of Press Release http://hugin.info/152918/R/1754164/591850.pdf

HUG#1754164